Importance There are multiple approved systemic treatments for atopic dermatitis.
Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in …

Purpose: For individuals with atopic dermatitis (AD), interpreting scientific papers that
present clinical outcomes including the Eczema Area and Severity Index (EASI) and …

Atopic dermatitis (AD) is a chronic inflammatory skin disease affecting tens of millions of
people globally. The causal relationship between metabolites and AD pathology has not yet …

Background Despite the widespread off‐label use of methotrexate (MTX) for the treatment of
atopic dermatitis (AD), there is limited high‐quality evidence on dosing regimens and …

This publication is an update of the “Consensus on the therapeutic management of atopic
dermatitis-Brazilian Society of Dermatology” published in 2019, considering the novel …

Background The main conventional systemic treatments for atopic dermatitis (AD) are
methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to …

Importance Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable
treatment options for pediatric patients with refractory moderate to severe atopic dermatitis …

Background/Objectives/Methods: Atopic dermatitis (AD) impacts various aspects of patients'
lives including personal life, psychological aspects/disturbances (eg, depression, anxiety, or …

Introduction Methotrexate (MTX) is a folic acid antagonist used in clinical practice in
oncology and rheumatology, as well as in the treatment of inflammatory skin conditions in …

Ciclosporin (CyA) and methotrexate (MTX) are frequently prescribed drugs for the treatment
of atopic dermatitis in children and young people. Both can affect renal function and frequent …